Researchers from Ruijin Hospital and Shanghai Jiao Tong University have patented molecular glue degraders, specifically eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers that are potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Jiangsu Vcare Pharmatech Co. Ltd. has described interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis and spondyloarthritis.

Singularity Pharma Ltd. has divulged mitragynine analogues that are potentially useful for the treatment of postoperative pain, depression, opioid dependence, opioid withdrawal, inflammatory and psychiatric disorders.

Hinova Pharmaceuticals Inc. has synthesized prodrugs of orforglipron (a glucagon-like peptide 1 receptor [GLP-1R] agonist) for the potential treatment of diabetes, obesity, hypertension, arteriosclerosis, cerebral infarction, arthritis, polycystic ovary syndrome and Parkinson’s disease, among others.

Solve Therapeutics Inc. has identified antibody-drug conjugates comprising antibodies covalently bound to camptothecin derivatives through a cleavable linker reported to be useful for the treatment of cancer.

Neolaia Inc. has divulged new quinoline- and quinazoline-carboxamide derivatives acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of atherosclerosis, cancer, inflammation, obesity, Alzheimer’s, autoimmune, cardiovascular and metabolic disorders.

Insilico Medicine Inc. has reported new NLRP3 inflammasome inhibitors potentially useful for the treatment of obesity, autoimmune and autoinflammatory diseases.

Incyte Corp. has synthesized new tricyclic heteroaryl compounds acting as non-receptor tyrosine-protein kinase TYK2 and/or tyrosine-protein kinase JAK1 inhibitors.

The National Center of Neurology and Tokyo University of Science in Japan have jointly developed new μ-opioid receptor antagonists potentially useful for the treatment of opioid dependence.

Mayo Foundation for Medical Education Research (MFMER) and the University of Minnesota have disclosed new bromodomain-containing protein 4 (BRD4; HUNK1) inhibitors potentially useful for the treatment of cancer, inflammatory and cardiovascular disorders.